High-Grade Glioma Clinical Trial and Pipeline Analysis 2026: Insights on MOA, ROA, Approved Therapies, and Clinical Trial Advancements by DelveInsight

According to DelveInsight's evaluation, the global High-Grade Glioma pipeline includes over 150 key companies actively engaged in developing more than 150 therapeutic candidates. The analysis highlights clinical trials, treatment approaches, mechanisms of action, routes of administration, and recent developments.

The High-Grade Glioma pipeline report provides a comprehensive commercial and clinical evaluation of drug candidates, covering stages from preclinical research to marketed therapies. It also offers detailed insights into each drug, including its mechanism of action, clinical trial progress, NDA approvals (if applicable), and development activities such as technologies, collaborations, mergers and acquisitions, funding, regulatory designations, and other key product-related information.

The report titled "High-Grade Glioma Pipeline Insight, 2026" by DelveInsight presents an in-depth overview of the current clinical development landscape along with future growth opportunities in the High-Grade Glioma market.

Request for free sample report @ https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the High-Grade Glioma Pipeline Report
• High-Grade Glioma Companies worldwide are actively focused on developing innovative therapies for High-Grade Glioma, achieving steady advancements over time.
• Leading High-Grade Glioma companies involved in the High-Grade Glioma treatment landscape include Everfront Biotech Co., Ltd., BioMimetix JV, LLC, Chimerix, Laminar Pharmaceuticals, Nationwide Children's Hospital, Rigel Pharmaceuticals, Orbus Therapeutics, Bayer, MedImmune, DNAtrix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Immunomic Therapeutics, Inovio Pharmaceuticals, and others.
• Promising High-Grade Glioma therapies under various stages of clinical development include Cerebraca wafer, BMX-001, ONC201, LAM561, Ribociclib, Olutasidenib + TMZ, Eflornithine + Lomustine, Regorafenib, Durvalumab (MEDI4736), Tasadenoturev (DNX-2401), Berubicin, VBI-1901, Paxalisib (GDC-0084), AV-GBM-1, MDNA55, VAL-083 (Dianhydrogalactitol), Pomalidomide, LP561A1 (2-OHOA), ITI-1000 (pp65 DC Vaccine), INO-5401 + INO-9012 + Cemiplimab (REGN2810), and others, which are expected to significantly influence the market in the coming years.
• In February 2026, FluoGuide A/S announced that the U.S. FDA approved its Investigational New Drug (IND) application for FG001, allowing the initiation of its first registration-supporting clinical trial in patients with High-Grade Glioma.
• In September 2025, FluoGuide reported positive feedback from the FDA following a pre-IND consultation, supporting its clinical study design. This progress paves the way for IND submission and eventual NDA filing for FG001, an intraoperative imaging agent. The company plans to conduct Phase II and Phase III trials in the U.S. to support regulatory approval.
• In June 2025, early results from the Phase I CLOVER-2 trial indicated that iopofosine I-131 demonstrated safety and clinical activity in pediatric patients with relapsed or refractory High-Grade Glioma, with manageable toxicity levels.
• In April 2025, preliminary findings from the Phase II IPAX-Linz study showed that TLX101 (131I-iodofalan), a targeted radiotherapy, exhibited a favorable safety profile and early signs of efficacy in recurrent High-Grade Glioma patients.
• In March 2025, Anova Enterprises initiated patient enrollment in a Phase I/IIa clinical trial of DB107 for brain tumors. This study aims to evaluate the clinical benefits of DB107 combined with standard of care in newly diagnosed High-Grade Glioma patients.
• In August 2024, Kiyatec presented data demonstrating that its 3D Predict Glioma test improved survival outcomes by accurately predicting chemotherapy response. The study showed a median progression-free survival increase of 5.8 months and overall survival improvement of 7.6 months in responders.
• In May 2024, Candel Therapeutics received FDA Orphan Drug Designation for CAN-3110, an oncolytic viral immunotherapy for recurrent High-Grade Glioma, including glioblastoma.
• In April 2024, Denovo Biopharma secured $11.8 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance DB107, a biomarker-driven gene therapy for High-Grade Glioma, including glioblastoma, through Phase I/II trials.

High-Grade Glioma Overview
High-Grade Glioma (HGG) refers to a group of aggressive brain tumors that originate from glial cells, which support and protect neurons. These tumors are classified as high-grade due to their rapid progression and invasive nature, making treatment challenging. Glioblastoma multiforme (GBM) is the most common and aggressive subtype. Symptoms may include headaches, seizures, cognitive impairments, and neurological deficits, depending on tumor location. Standard treatment approaches typically involve surgery, radiation therapy, and chemotherapy, though overall prognosis remains poor.

Get a free sample report: https://www.delveinsight.com/report-store/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging High-Grade Glioma Drugs in Clinical Development
• Cerebraca wafer: Everfront Biotech Co., Ltd.
• BMX-001: BioMimetix JV, LLC
• ONC201: Chimerix
• LAM561: Laminar Pharmaceuticals
• Ribociclib: Nationwide Children's Hospital
• Olutasidenib + TMZ: Rigel Pharmaceuticals
• Eflornithine + Lomustine: Orbus Therapeutics
• Regorafenib: Bayer
• Durvalumab (MEDI4736): MedImmune
• Tasadenoturev (DNX-2401): DNAtrix
• Berubicin: CNS Pharmaceuticals
• VBI-1901: VBI Vaccines
• Paxalisib (GDC-0084): Kazia Therapeutics
• AV-GBM-1: Aivita Biomedical
• MDNA55: Medicenna Therapeutics
• VAL-083: DelMar Pharmaceuticals
• Pomalidomide: Bristol-Myers Squibb
• LP561A1: Laminar Pharmaceuticals
• ITI-1000: Immunomic Therapeutics
• INO-5401 + INO-9012 + Cemiplimab: Inovio Pharmaceuticals

High-Grade Glioma Route of Administration (ROA)
The report evaluates therapies based on multiple administration routes, including:
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous

High-Grade Glioma Molecule Type Classification
Therapies are categorized based on molecule types such as:
• Gene therapies
• Small molecules
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

High-Grade Glioma Pipeline Therapeutics Assessment
• Assessment by product type
• Segmentation by development stage and product type
• Evaluation by route of administration
• Stage-wise classification based on ROA
• Analysis by molecule type
• Stage-wise segmentation by molecule type

DelveInsight's report covers more than 150 therapies across various development stages, including:
• Phase III (late-stage)
• Phase II (mid-stage)
• Phase I (early-stage)
• Preclinical and discovery-stage candidates
• Discontinued or inactive programs

Download the full pipeline report: https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key High-Grade Glioma Companies in the Market
Major companies involved in High-Grade Glioma therapeutics development include Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, and others.

High-Grade Glioma Pipeline Analysis Insights
• The report provides detailed insights into companies developing High-Grade Glioma therapies and their respective pipelines.
• It categorizes drug candidates based on early, mid, and late stages of development.
• Key players are engaged in targeted therapy development, including both active and inactive programs.
• Drug candidates are analyzed based on development stage, route of administration, target receptors, therapy type (mono or combination), mechanism of action, and molecular classification.
• The report also evaluates collaborations, licensing agreements, and funding activities supporting future market growth.
The analysis is based on data sourced from proprietary databases, company and academic platforms, clinical trial registries, conferences, SEC filings, investor presentations, and other credible industry sources.

Download sample report: https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

High-Grade Glioma Market Drivers
• Rising prevalence of High-Grade Glioma and improved access to advanced diagnostic and treatment options are key factors driving market growth.

High-Grade Glioma Market Challenges
• High treatment costs and associated side effects remain major barriers to market expansion.

High-Grade Glioma Pipeline Report Scope
• Coverage: Global
• Key High-Grade Glioma Companies: Everfront Biotech, BioMimetix, Chimerix, Bayer, MedImmune, DNAtrix, CNS Pharmaceuticals, Kazia Therapeutics, and others
• Key High-Grade Glioma Therapies: Cerebraca wafer, BMX-001, ONC201, LAM561, Ribociclib, Regorafenib, Durvalumab, Berubicin, Paxalisib, and more
• Therapeutic Scope: Marketed and emerging therapies
• Market Dynamics: Drivers and barriers shaping the High-Grade Glioma market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.